Merck
PD-L1 Cutoff for TNBC Keytruda Benefit Confirmed in KEYNOTE Analyses, But Questions Linger
Findings confirmed advanced TNBC patients with PD-L1 10 or above benefit from Keytruda, but other data show PD-L1 doesn't predict benefit in earlier-stage TNBC.Â
NGM Biopharmaceuticals, Merck to Study ILT2/4 Inhibitor Plus Keytruda in Solid Tumors
The companies inked a collaboration to study the drug combination in advanced solid tumors with elevated expression of ILT2 and ILT4.
AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer
The FDA is evaluating the application for the PARP inhibitor in BRCA1/2-mutated early-stage breast cancer and may make a decision in early 2022.
Merck Q3 Revenues Grow 20 Percent With Keytruda as Top Seller
The company is expecting the blockbuster PD-1 immune checkpoint inhibitor to be increasingly used to treat earlier stages of cancer.
Hummingbird Bioscience, Merck to Study HMBD-002 With Keytruda in Various Solid Tumors
The firms plan to evaluate the anti-VISTA and anti-PD-1 therapies in a clinical trial for TNBC, NSCLC, and other cancers with high VISTA expression.